Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JNJ-63898081 |
Synonyms | |
Therapy Description |
JNJ-63898081 is a bispecific antibody that binds to prostate specific membrane antigen (PSMA) and CD3, which potentially activates cytotoxic T-lymphocytes resulting in increased death of PSMA-expressing tumor cells (NCI Thesaurus). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JNJ-63898081 | JNJ63898081|JNJ 63898081 | CD3 Antibody 99 PSMA Antibody 20 | JNJ-63898081 is a bispecific antibody that binds to prostate specific membrane antigen (PSMA) and CD3, which potentially activates cytotoxic T-lymphocytes resulting in increased death of PSMA-expressing tumor cells (NCI Thesaurus). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03926013 | Phase I | JNJ-63898081 | A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors | Completed | USA | CAN | 0 |